Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Towards a vaccination against malaria]

P Ambroise-Thomas1

  • 1Département de parasitologie-mycologie médicale et moléculaire, CNRS EP 78, faculté de médecine, Grenoble, France.

La Revue De Medecine Interne
|January 1, 1995
PubMed
Summary

Despite decades of challenges, the first human malaria vaccine (SPf66) shows modest success, protecting against disease but not parasitemia in 40% of cases. This marks a significant step forward in malaria vaccine development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Meeting of the Société de pathologie exotique - Limoges Institute of Tropical Neurology, 23rd April 2010. Dementia in the tropics. Epilepsy in the tropics].

Bulletin de la Societe de pathologie exotique (1990)·2010
Same author

[Chagas disease].

Bulletin de la Societe de pathologie exotique (1990)·2010
Same author

[The bulletin of the SPE: continuity within change].

Bulletin de la Societe de pathologie exotique (1990)·2010
Same author

[Centenary of the Society of Exotic Pathology . Introduction ].

Bulletin de la Societe de pathologie exotique (1990)·2008
Same author

[Sleep disorders and hypnotic agents: a real public health issue].

Annales pharmaceutiques francaises·2007
Same author

[Genomic, molecular biology and malaria: new medical perspectives?].

Bulletin de la Societe de pathologie exotique (1990)·2004

Area of Science:

  • Parasitology
  • Immunology
  • Vaccinology

Context:

  • Malaria vaccine development has faced significant challenges for over 20 years.
  • The complexity of Plasmodium parasites, multiple life cycle targets, adjuvant requirements, and imperfect models hinder progress.

Purpose:

  • To report on the first successful human trials of a synthetic anti-malarial vaccine, SPf66.
  • To evaluate the efficacy of SPf66 in protecting against malaria disease and parasitemia.

Summary:

  • The synthetic antigen SPf66 demonstrated protection against malaria disease in approximately 40% of vaccinated individuals in trials in South America and East Africa.
  • While SPf66 did not prevent parasitemia, it represents the first successful anti-malarial vaccination in humans, offering a crucial advancement.
  • Future vaccine strategies, including anti-gametocyte vaccines and DNA-vaccines, hold promise for improved efficacy.

Impact:

  • This research marks a pivotal moment, validating the concept of human anti-malarial vaccination.
  • Further advancements are necessary, but the development of effective malaria vaccines is now a realistic prospect.
  • Eradication of malaria solely through vaccination is unlikely due to the disease's complex epidemiology; integrated control strategies are essential.

Related Experiment Videos